Rachel Lenington - Jan 19, 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role
Chief Operating Officer
Signature
/s/ Glenna Mileson, Attorney-in-Fact for Rachel Lenington
Stock symbol
ATHA
Transactions as of
Jan 19, 2023
Transactions value $
$0
Form type
4
Date filed
1/23/2023, 04:45 PM
Previous filing
Jun 24, 2022
Next filing
Jan 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATHA Stock Option (Right to Buy) Award $0 +200K $0.00 200K Jan 19, 2023 Common Stock 200K $3.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.